Actionable mutations in muscle-invasive bladder cancer Journal Article


Authors: Bambury, R. M.; Rosenberg, J. E.
Article Title: Actionable mutations in muscle-invasive bladder cancer
Abstract: PURPOSE OF REVIEW: Thirty-five percent of bladder cancer patients either present with or develop muscle-invasive disease. The current standard of care for these patients is neoadjuvant chemotherapy followed by radical cystoprostatectomy or combined chemoradiotherapy. Despite these therapies, approximately 50% of patients will relapse after definitive locoregional treatment and eventually succumb to their disease. RECENT FINDINGS: Therapies targeted at altered genetic pathways have proven efficacy in localized solid tumors including breast cancer, head and neck cancer and GIST. No such treatments have proven clinical benefit in bladder cancer, but targets under active investigation include HER2, epidermal growth factor receptors, fibroblast growth factor receptor 3, mTOR and others. Efforts are also underway to genetically define the subgroup of patients, which benefit from systemic platinum-based chemotherapy in this setting. SUMMARY: Ongoing clinical trials are investigating the role of treatments targeted at actionable genetic mutations in bladder cancer. The key to maximizing the potential benefit from this treatment approach will be the identification of predictive biomarkers of response, the identification of safe combinations which block multiple signaling molecules synchronously, and the availability of faster, cheaper genetic testing in the clinic. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Keywords: bladder cancer; targeted therapy; urothelial cancer; personalized medicine; actionable mutations
Journal Title: Current Opinion in Urology
Volume: 23
Issue: 5
ISSN: 0963-0643
Publisher: Lippincott Williams & Wilkins  
Date Published: 2013-09-01
Start Page: 472
End Page: 478
Language: English
DOI: 10.1097/MOU.0b013e328363a3cd
PROVIDER: scopus
PUBMED: 23907505
DOI/URL:
Notes: --- - "Export Date: 4 September 2013" - "CODEN: CUOUE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Eric Rosenberg
    510 Rosenberg
  2. Richard Bambury
    34 Bambury